CDK4/6 inhibitorFDA-approvedFirst-line
Palbociclib
How it works
Blocks the CDK4/6 enzymes, which are involved in cell growth and division.
Cancer types
Breast Cancer— Hormone receptor-positive
Efficacy
Clinical trials have shown that palbociclib can improve progression-free survival in patients with hormone receptor-positive metastatic breast cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comorbidities Affect Outcomes for Breast Cancer Patients on Palbociclib | Breast Cancer | observational | Median overall survival durations were 48.8 months for patients with a Charlson Comorbidity Index score of 0, 39.0 months for patients with a score of 1-2, and 31.6 months for patients with a score of 3+. | Source → |
| Testing Palbociclib and Avelumab in Metastatic Triple Negative Breast Cancer | Breast Cancer | phase-1 | — | Source → |
| Using Text Messages to Help People Take Palbociclib for Breast Cancer | Breast Cancer | preclinical | — | Source → |
| Testing Palbociclib and Binimetinib in RAS-Mutant Cancers | Pancreatic Cancer | phase-2 | — | Source → |
| Palbociclib in Metastatic Prostate Cancer: A Clinical Trial | Prostate Cancer | phase-2 | — | Source → |
| New Long-Acting Palbociclib Injection for Metastatic Breast Cancer | Breast Cancer | lab-study | — | Source → |
| Lab Test Models Breast Cancer Cells to Study Palbociclib Effectiveness | Breast Cancer | lab-study | — | Source → |
| New Insights into Treating Low-Grade Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Palbociclib and Neutropenia in Metastatic Breast Cancer | Breast Cancer | observational | The 30-month PFS rate was 75% with the dose of 100 mg, 90.9% with 75 mg, and 97.2% with the dose of 125 mg. | Source → |
| Palbociclib's Potential in Leukemia Treatment | Leukemia | review | — | Source → |
| Cyclin Dependent Kinase Inhibitors in Metastatic Breast Cancer | Breast Cancer | observational | In patients receiving palbociclib, a better median progression-free survival (PFS) was observed in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 1 (27.3 months,p-value <0.0001), de novo disease (17.5 months,p-value 0.0155), first line hormonal therapy (22.5 months,p-value <0.0001) and no prior chemotherapy (20.3 months,p-value 0.0001). | Source → |
| Inavolisib Combination Not Cost-Effective for Advanced Breast Cancer | Breast Cancer | phase-3 | Inavolisib provided an additional 0.6 QALYs compared to placebo. | Source → |
| Palbociclib Effectiveness in Indian Breast Cancer Patients | Breast Cancer | observational | The real-world response rate and the real-world clinical benefit rate across treatment lines were 68% and 75.3%, respectively. | Source → |
| Intermittent Palbociclib Use in Metastatic Breast Cancer During Economic Crisis | Breast Cancer | observational | Intermittent discontinuation statistically reduces PFS by 26%. | Source → |
| Real-world effectiveness of palbociclib in breast cancer treatment | Breast Cancer | meta-analysis | First-line palbociclib+AI MMPFS (22.5 months, 95% CI = 19.5 to 31.8) aligned with PALOMA-1/2 pooled mPFS (23.9, 95% CI = 20.2 to 27.6). | Source → |
| Palbociclib and Endocrine Therapy for Metastatic Breast Cancer in Japan | Breast Cancer | observational | The median progression-free survival was 26.6 months. | Source → |
| Real-world study of palbociclib and fulvestrant for breast cancer | Breast Cancer | observational | Median real-world progression-free survival was 19.6 months (95% CI 15.2-23.6) | Source → |
| Understanding Resistance to Breast Cancer Treatment | Breast Cancer | lab-study | — | Source → |
| New Combination Therapy Shows Promise for Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| G Protein Estrogen Receptor Linked to Resistance to Breast Cancer Treatment | Breast Cancer | lab-study | — | Source → |
| Palbociclib plus endocrine therapy effective in Japanese breast cancer patients | Breast Cancer | observational | Median progression-free survival was 24.5 months for first-line treatment and 14.5 months for second-line treatment. | Source → |
| Study Examines Combination Therapy for Advanced Breast Cancer | Breast Cancer | phase-2 | The median progression-free survival on F + P + A was 8.1 months (HR 0.75 [90% CI, 0.50 to 1.12]; = .23). | Source → |
| Comparing Two Cancer Treatments in Younger Women | Breast Cancer | observational | The median progression-free survival was 24.05 months for palbociclib and 24.41 months for ribociclib. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.